Description

Ipamorelin 2mg – Selective Growth Hormone Secretagogue Research Peptide

Ipamorelin 2mg is a synthetic pentapeptide investigated in scientific research involving growth hormone secretion, ghrelin receptor signalling and endocrine regulation. Also known as NNC-26-0161, Ipamorelin belongs to the growth hormone secretagogue family and has been studied in laboratory, animal and selected human clinical investigations.

Ipamorelin 2mg contains five amino acid residues, including non-natural amino acid components. Its reference sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. This molecular structure distinguishes Ipamorelin from growth hormone-releasing peptides such as GHRP-2, GHRP-6 and Hexarelin.

Early preclinical research demonstrated that Ipamorelin stimulated growth hormone secretion while producing comparatively limited ACTH and cortisol responses under the conditions studied. This endocrine selectivity made the molecule an important subject of growth hormone secretagogue research.

However, Ipamorelin 2mg is not an established approved medicine for weight loss, muscle growth, growth hormone deficiency or anti-ageing in the United Kingdom. Its human therapeutic effectiveness and long-term safety remain insufficiently established.

What Is Ipamorelin 2mg?

Ipamorelin 2mg refers to a product labelled as containing 2mg of the synthetic growth hormone-releasing peptide Ipamorelin.

Ipamorelin is a pentapeptide developed through research into synthetic growth hormone secretagogues.

A growth hormone secretagogue is a compound capable of stimulating growth hormone release through biological signalling pathways.

Ipamorelin acts through the growth hormone secretagogue receptor system, which is also associated with the naturally occurring hormone ghrelin.

Unlike recombinant human growth hormone, Ipamorelin does not contain the growth hormone protein itself.

Instead, it has been investigated for its ability to influence the body’s endogenous growth hormone secretion.

Research involving Ipamorelin has contributed to understanding pituitary function, receptor pharmacology and endocrine selectivity.

Ipamorelin 2mg Product Specifications

• Product Name: Ipamorelin 2mg
• Scientific Name: Ipamorelin
• Alternative Names: NNC-26-0161, Ipamorelin peptide
• Classification: Synthetic growth hormone secretagogue
• Peptide Family: Growth hormone-releasing peptides
• Peptide Length: 5 amino acid residues
• Reference Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
• Reference Molecular Formula: C38H49N9O5
• Reference Molecular Weight: Approximately 711.9 g/mol
• CAS Number: 170851-70-4
• PubChem CID: 9831659
• Research Target: Growth hormone secretagogue receptor (GHS-R1a)
• Research Category: Endocrinology and peptide biochemistry
• Primary Research Focus: Growth hormone secretion
• Additional Research Focus: Receptor selectivity and endocrine signalling
• Labelled Quantity: 2mg
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

These specifications describe the reference Ipamorelin free-base molecule. Commercial preparations may differ in salt form, counterion content, physical presentation and purity. The identity and composition of a particular Ipamorelin 2mg batch should be confirmed using manufacturer documentation and suitable analytical testing.

Understanding the Molecular Structure of Ipamorelin

Ipamorelin is a synthetic peptide containing five amino acid residues.

Its commonly referenced sequence is:

Aib-His-D-2-Nal-D-Phe-Lys-NH2

The sequence contains alpha-aminoisobutyric acid (Aib), histidine, D-2-naphthylalanine, D-phenylalanine and lysine.

The C-terminal lysine residue is amidated.

Several residues are non-natural or have modified stereochemistry.

These structural features distinguish Ipamorelin from many naturally occurring peptides.

Researchers studying Ipamorelin 2mg should verify the complete sequence, stereochemistry, C-terminal amidation and expected molecular mass.

How Does Ipamorelin Work?

Ipamorelin acts as a growth hormone secretagogue in experimental systems.

Its effects are associated with the growth hormone secretagogue receptor, commonly called GHS-R1a or the ghrelin receptor.

GHS-R1a participates in endocrine signalling involved in growth hormone regulation.

Activation of this receptor system can stimulate growth hormone release from the anterior pituitary gland.

Growth hormone participates in growth, metabolism and the regulation of insulin-like growth factor 1.

However, Ipamorelin does not reproduce all the effects of recombinant human growth hormone.

Early preclinical studies reported growth hormone responses following Ipamorelin exposure.

These studies also identified comparatively limited ACTH and cortisol responses under the conditions examined.

However, the endocrine selectivity observed in animals does not establish complete hormone specificity or long-term safety in humans.

Scientific Research Into Ipamorelin 2mg

1. Ipamorelin 2mg and Growth Hormone Secretion Research

Growth hormone is produced by somatotroph cells in the anterior pituitary gland.

Its secretion is regulated by several interacting biological signals.

Ipamorelin has been investigated for its ability to stimulate growth hormone release.

A foundational 1998 study reported growth hormone-releasing activity in rat pituitary cells and animal models.

These findings established Ipamorelin as a growth hormone secretagogue in the experimental systems studied.

However, acute hormone responses do not establish therapeutic effectiveness for obesity, muscle growth or anti-ageing.

2. Ipamorelin and Ghrelin Receptor Research

The growth hormone secretagogue receptor is also known as the ghrelin receptor.

Ghrelin is a naturally occurring hormone involved in appetite, energy regulation and growth hormone signalling.

Ipamorelin has been investigated as a synthetic agonist of the GHS-R1a receptor system.

Researchers have used synthetic secretagogues to investigate how receptor activation influences pituitary hormone release.

However, receptor activity does not establish predictable clinical benefits.

3. Ipamorelin 2mg and Pituitary Function Research

The anterior pituitary gland produces several hormones involved in growth, reproduction, metabolism and stress responses.

Ipamorelin research has focused particularly on growth hormone secretion.

Researchers have also measured other pituitary-associated hormones to evaluate endocrine selectivity.

These investigations help clarify differences among synthetic growth hormone-releasing peptides.

4. Ipamorelin and ACTH Research

Adrenocorticotropic hormone, abbreviated ACTH, is produced by the anterior pituitary gland.

ACTH participates in regulating cortisol production by the adrenal glands.

Early animal research found that Ipamorelin produced comparatively limited ACTH responses under the experimental conditions examined.

This finding distinguished Ipamorelin from some other growth hormone secretagogues.

However, it does not establish that Ipamorelin has no effect on ACTH in all circumstances.

5. Ipamorelin 2mg and Cortisol Research

Cortisol is involved in metabolism, immune regulation and physiological stress responses.

Some synthetic growth hormone secretagogues can influence cortisol secretion.

The original Ipamorelin pharmacology study reported that Ipamorelin did not significantly increase cortisol beyond the comparison response to growth hormone-releasing hormone in the animal model studied.

This result contributed to interest in its endocrine selectivity.

However, long-term human cortisol effects remain insufficiently established.

6. Ipamorelin and Prolactin Research

Prolactin is a pituitary hormone involved in reproductive and other physiological functions.

The original preclinical Ipamorelin study measured prolactin responses alongside other pituitary hormones.

Under the experimental conditions examined, Ipamorelin did not produce significant prolactin changes.

However, these observations should not be interpreted as proof of complete endocrine selectivity in humans.

7. Ipamorelin 2mg and Growth Hormone Secretagogue Selectivity

Endocrine selectivity describes the degree to which a compound influences one hormonal pathway rather than several.

Ipamorelin was investigated as a comparatively selective growth hormone secretagogue.

In a 1998 study, researchers compared Ipamorelin with GHRP-2, GHRP-6 and growth hormone-releasing hormone.

Ipamorelin demonstrated growth hormone-releasing activity with comparatively limited ACTH and cortisol responses in the animal models studied.

However, selectivity is relative and depends on the experimental conditions.

8. Ipamorelin and Growth Hormone-Releasing Hormone Research

Growth hormone-releasing hormone, or GHRH, is a naturally occurring hypothalamic hormone.

GHRH stimulates growth hormone secretion through its own receptor system.

Ipamorelin acts through a different receptor pathway associated with growth hormone secretagogues.

Researchers have compared the hormonal responses produced by these different signalling systems.

These comparisons help clarify the regulation of growth hormone secretion.

9. Ipamorelin 2mg and IGF-1 Research

Insulin-like growth factor 1, abbreviated IGF-1, participates in many growth hormone-related physiological processes.

Growth hormone can influence IGF-1 production.

However, an acute increase in growth hormone does not guarantee a proportional or sustained increase in IGF-1.

The long-term effects of Ipamorelin on IGF-1 regulation in humans remain insufficiently established.

10. Ipamorelin and Peptide Structure-Activity Research

Structure-activity relationship research investigates how molecular changes influence biological properties.

Ipamorelin contains non-natural amino acid residues and a C-terminal amide.

These features distinguish it from related growth hormone-releasing peptides.

Researchers can compare Ipamorelin with GHRP-2, GHRP-6 and Hexarelin to investigate differences in receptor activity and endocrine responses.

11. Ipamorelin 2mg and Gastrointestinal Research

Ghrelin receptor signalling is involved in gastrointestinal physiology as well as endocrine regulation.

Ipamorelin has been investigated in clinical research involving postoperative gastrointestinal motility.

However, clinical development did not establish Ipamorelin as an approved treatment for postoperative ileus.

The results of gastrointestinal studies should not be used to imply that Ipamorelin is a proven digestive treatment.

12. Ipamorelin and Clinical Safety Research

Clinical safety evaluation requires assessment of adverse events, exposure, formulation quality and long-term outcomes.

Ipamorelin has undergone limited human clinical investigation.

However, the available evidence does not establish a comprehensive safety profile for routine therapeutic use.

Regulatory reviews have identified concerns involving serious adverse events in clinical investigations and uncertainties relating to peptide impurities and immunogenicity.

13. Ipamorelin 2mg and Metabolic Research

Growth hormone participates in lipid, protein and carbohydrate metabolism.

Because Ipamorelin can stimulate growth hormone release, it has attracted interest in metabolic research.

However, increased growth hormone secretion does not automatically establish improved metabolic health or body composition.

There is insufficient reliable human clinical evidence demonstrating that Ipamorelin 2mg safely produces meaningful fat reduction.

14. Ipamorelin and Peptide Stability Research

Peptide stability depends on amino acid composition, salt form, formulation and environmental conditions.

Ipamorelin contains several non-natural amino acid components.

These features may influence its biochemical characteristics.

However, the stability and shelf life of a commercial Ipamorelin 2mg preparation require product-specific verification.

15. Ipamorelin 2mg and Research Reproducibility

Reliable scientific research depends on accurately characterised experimental materials.

Differences in peptide identity, salt form, purity and formulation may influence experimental results.

Researchers evaluating Ipamorelin 2mg should confirm the sequence, stereochemistry, molecular mass and batch-specific analytical documentation.

Ipamorelin 2mg vs GHRP-2

Ipamorelin and GHRP-2 are different synthetic growth hormone secretagogues.

Both have been investigated for their ability to stimulate growth hormone secretion.

However, their amino acid sequences and endocrine profiles differ.

The original Ipamorelin study reported comparatively limited ACTH and cortisol responses with Ipamorelin in the animal models examined, while GHRP-2 produced increases in these hormones.

These findings do not establish that Ipamorelin is safer or more effective in humans.

Ipamorelin 2mg vs GHRP-6

Ipamorelin and GHRP-6 belong to the growth hormone secretagogue family.

Both have demonstrated growth hormone-releasing activity in experimental systems.

However, the peptides have different molecular structures.

Preclinical comparisons identified differences in ACTH and cortisol responses.

Research findings involving GHRP-6 should not automatically be attributed to Ipamorelin.

Ipamorelin 2mg vs Hexarelin

Ipamorelin is a five-amino-acid peptide, while Hexarelin is a six-amino-acid peptide.

Both have been investigated as growth hormone secretagogues.

However, they differ in amino acid sequence, molecular weight and experimental endocrine profiles.

Hexarelin has demonstrated ACTH, cortisol and prolactin responses in selected human physiological studies.

Ipamorelin’s comparatively selective profile was primarily established in preclinical research.

Ipamorelin 2mg vs CJC-1295

Ipamorelin and CJC-1295 are different classes of research peptides.

Ipamorelin is a growth hormone secretagogue associated with ghrelin receptor signalling.

CJC-1295 is a modified growth hormone-releasing hormone analogue.

Although both are investigated in relation to growth hormone regulation, their molecular structures and receptor pathways differ.

Ipamorelin 2mg and Weight-Loss Claims

Ipamorelin 2mg is sometimes discussed online in connection with fat loss and weight management.

However, the principal scientific evidence concerns growth hormone secretion and receptor pharmacology.

There is insufficient reliable human clinical evidence demonstrating that Ipamorelin safely reduces body fat or treats obesity.

It should not be marketed as a proven weight-loss peptide.

Ipamorelin 2mg and Muscle Growth Claims

Ipamorelin is sometimes associated with muscle development because it stimulates growth hormone release in experimental systems.

However, increased growth hormone secretion does not automatically produce clinically meaningful increases in muscle mass or strength.

There is insufficient reliable evidence that Ipamorelin 2mg safely improves muscle development or athletic performance in humans.

Ipamorelin 2mg Research Quality and Documentation

Important considerations when evaluating Ipamorelin 2mg research material include:

• Verification of the complete peptide sequence
• Confirmation of the five-amino-acid structure
• Verification of the alpha-aminoisobutyric acid residue
• Confirmation of the D-2-naphthylalanine residue
• Verification of D-phenylalanine stereochemistry
• Confirmation of C-terminal amidation
• Verification of the expected molecular mass
• Identification of the supplied salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 2mg quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Product-specific storage and stability documentation
• Clearly stated research-use classification

Storage and Handling of Ipamorelin 2mg

Ipamorelin 2mg should be stored according to verified manufacturer instructions.

Storage requirements depend on the peptide’s salt form, physical presentation, formulation and packaging.

Researchers should not assume that all Ipamorelin preparations have identical stability or shelf-life characteristics.

Laboratory handling should follow relevant safety documentation and institutional procedures.

Ipamorelin 2mg Safety and Scientific Limitations

Ipamorelin 2mg is an investigational research material without an established long-term human therapeutic safety profile.

Early animal studies demonstrated growth hormone-releasing activity and comparatively selective endocrine responses.

However, these findings do not establish that the compound is safe for human administration.

Regulatory reviews have raised concerns about peptide aggregation, impurities, potential immunogenicity and serious adverse events reported during clinical investigations.

There is insufficient reliable evidence demonstrating safe and effective human use for weight loss, muscle growth, growth hormone deficiency or anti-ageing.

Ipamorelin is not an established approved UK medicine for these purposes.

Research-grade material should not be assumed suitable for human administration.

The labelled 2mg quantity is not a human dosing recommendation.

Frequently Asked Questions About Ipamorelin 2mg

What is Ipamorelin 2mg?

Ipamorelin 2mg is a product listing for a synthetic five-amino-acid growth hormone secretagogue with a labelled quantity of 2mg.

What is another name for Ipamorelin?

Ipamorelin is also known by the research designation NNC-26-0161.

What is the Ipamorelin peptide sequence?

The reference sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2.

How many amino acids does Ipamorelin contain?

Ipamorelin contains five amino acid residues.

What is the molecular formula of Ipamorelin?

The reference molecular formula is C38H49N9O5.

What is the molecular weight of Ipamorelin?

The reference molecular weight is approximately 711.9 g/mol.

What is the CAS number for Ipamorelin?

The commonly listed CAS number is 170851-70-4.

Does Ipamorelin stimulate growth hormone?

Yes. Preclinical studies have demonstrated growth hormone-releasing activity in experimental systems.

Does Ipamorelin affect cortisol?

Early animal research found comparatively limited cortisol responses under the conditions studied. This does not establish the absence of cortisol effects in all circumstances.

Does Ipamorelin affect prolactin?

The original preclinical study did not report significant prolactin changes under the experimental conditions examined.

Is Ipamorelin the same as GHRP-2?

No. Ipamorelin and GHRP-2 are different synthetic peptides with distinct molecular structures.

Is Ipamorelin a weight-loss peptide?

Ipamorelin is not an established approved treatment for obesity or weight management.

Does Ipamorelin build muscle?

There is insufficient reliable human clinical evidence demonstrating safe increases in muscle mass or strength.

Is Ipamorelin approved for human use?

Ipamorelin is not an established approved UK medicine for weight loss, muscle growth or anti-ageing.

What does Ipamorelin 2mg mean?

The designation refers to a labelled quantity of 2mg of research material, not a recommended human dose.

Ipamorelin 2mg – Scientific Product Summary

Ipamorelin 2mg is a synthetic five-amino-acid growth hormone secretagogue also known as NNC-26-0161.

Its reference sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular weight of approximately 711.9 g/mol.

Published research has investigated Ipamorelin in relation to growth hormone secretion, ghrelin receptor signalling and endocrine selectivity.

Although preclinical studies demonstrate growth hormone-releasing activity, human therapeutic effectiveness and long-term safety remain insufficiently established.

Researchers evaluating Ipamorelin 2mg should verify molecular identity, stereochemistry, purity, salt form, labelled quantity and batch-specific analytical documentation.